About Us

​Dr. Sipple’s interests focus social impact tech that has under-penetrated the marketplace. He serves on the board of directors of Kinuu, gamified Occupational Therapy for Autism, Asperger, ADHD, and Dyslexia. The average wait for an Autism Clinic is one year. Hedge funds are active acquirers of such clinics, which profit an annual average of $10 Million USD. Lowering cost and caregiver burden with a home-based therapy such as Brainyact by Kinuu, should outcomes and data continue to bear out, has a substantial social impact and will be a welcome addition to the marketplace. Those in underserved and rural areas, without access to special needs services, will particularly benefit.  Kinuu’s preliminary data demonstrates shifts of 22-26% across 6 different domains in the developmentally disabled.  Blue Cross Blue Shield of Minnesota presently engaging with Kinuu, endorsing it as a modality for it’s customers.   https://brainyact.com/

Dr. Sipple has recently joined the Board of Directors at Thera Clean. Oxygen Microbubbles, first pioneered in the cardiac space for use in echocardiography, have been repurposed for cleaning in pets. Billions of small oxygen microbubbles, smaller than a red blood cell, perfuse tissue and penetrate and lift out toxins from the skin. The high oxygen content has been observed to not only clean but heal wounds and infections. In case studies from the Department of Dermatology at Northwestern University, TheraClean has radically improved previously untreatable condition known as ichthyosis, a rare scaling skin disorder. Given this response, applications for broader use, such as skin aesthetics, acne, wounds, diabetic feet, autoimmune rash manifestations, and challenging polymicrobial infections, are on the horizon.  Results of these case studies were presented at the Mayo Clinic Wound symposium in February 2025.  Thera Clean is now FDA registered for use in humans, and studies are underway investigating the recalcitrant condition Epidermolysis Bullosa at Northwestern University. process with the FDA use in humans.  Thera-Clean® Microbubbles: The Best Pet Cleaning System   Mayo Clinic Wound Symposium: The Edges of Wound Care 2025 | Mayo Clinic School of Continuous Professional Development | CME Course Conference  https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=16616

​Dr. Sipple serves as an advisor to Niraxx, Havard founded photobiomodulation company lead by Joshua Chen, CEO, and Dr. Paolo Cassano, MD Phd, director of Photobiomodulation at Massachusetts General Hospital.  With over 10,000 studies on photobiomodulation, it’s use cases are  growing rapidly.  Evidence lead applications include mental health, neurodegenerative disease, fertility, soft tissue pain and performance recovery.  Niraxx has patent a textile with photobiomodulation woven directly into clothing, making wearability practical and stigma free.  Niraxx: Recharge Your Mind. Recharge Your Life.Brain Photobiomodulation Clinic | Department of Psychiatry | Massachusetts General Hospital

Neuro20, FDA cleared with 5 indications and Medicare code approved functional electrical stimulation, is yet another example of non-pharmacologic disruptive tech that Dr. Sipple advises.  Developed by DJ Schmidt, a post US Marine Special Forces, former CIA contractor and past head United States Federal Air Marshall’s post September 11^th, Mr Schmidt was blow up by an IED.  He subsequently traveled the world, including visits to India and the Shaolin Temple in China to harness the power of functional electrical stimulation in the wearable Neuro20 suit.  Use cases are underway at distinguished rehabilitation facilities including the Shriley Ryan Ability Lab, Johns Hopkins and Shephard Rehabilitation Center for a variety of conditions, with initial focus being neurodegenerative conditions, such as Multiple Sclerosis.  Case study data of 25 minute use, twice daily over 4 months restored ambulation in an MS patient previously unable to walk. Neuro20 is now partnered with Medtech Makers Lab and Medilink Midlands of the United Kingdom National Health Service, where further studies to expand indications of use are anticipated.  Home – Neuro20

On the funding side of Innovation, Dr. Sipple is partnered with DueDash Investment Management Platform.  DueDash matches start ups with investors.  By providing CRM, data room,  deal flow management, deal origination, fundraising/SPV, along with ongoing communication with a network of investors.  Investor network included angels, venture capital, private equity, investment banking and corporate https://duedash.com/